llph Antibody

What is LLPH protein and what are its known biological functions?

LLPH (Protein LLP homolog) is a 15.2-18 kDa protein involved in cellular metabolism, particularly in the conversion of lactate. In hippocampal neurons, LLPH plays a significant role in regulating dendritic and spine growth as well as synaptic transmission . The protein is also known by several alternative names including C12orf31, cPERP-G, and Protein LAPS18-like . LLPH is associated with nucleolus localization and has poly(A) RNA binding capabilities . The human LLPH protein consists of 129 amino acids and has functions related to transcription factors, signal transduction, and cell development & differentiation .

What types of LLPH antibodies are commercially available and how do they differ?

LLPH antibodies are available in three main forms:

• Polyclonal antibodies: Derived from multiple B cell lineages and recognize multiple epitopes on the LLPH protein. These generally show broader reactivity but potentially lower specificity.

• Monoclonal antibodies: Produced from a single B cell clone and recognize a single epitope, offering higher specificity but potentially limited application versatility.

• Recombinant antibodies: Engineered antibodies produced through recombinant DNA technology.

Comparative performance data shows that recombinant antibodies generally perform better than polyclonal or monoclonal antibodies across different applications:

This superior performance of recombinant antibodies may be due to enhanced internal characterization by commercial suppliers .

How should I validate the specificity of an LLPH antibody for my research?

The gold standard for antibody validation is using parental versus knockout (KO) cell lines. This approach is considered superior to orthogonal validation strategies, particularly for immunofluorescence applications . The validation process should include:

• Western blot validation: Test the antibody on lysates from both wild-type cells expressing LLPH and CRISPR knockout cells lacking LLPH.

• Immunoprecipitation validation: Confirm that the antibody can specifically enrich LLPH from non-denaturing cell lysates.

• Immunofluorescence validation: Image a mosaic of parental and KO cells in the same visual field to reduce imaging and analysis biases .

Consider that while genetic validation approaches (using KO or knockdown cells) yield more reliable results, they're more costly than orthogonal approaches. Research indicates that while orthogonal strategies may be somewhat suitable for Western blot validation (with 80% success rate), genetic strategies generate far more robust characterization data for immunofluorescence (80% success rate compared to only 38% for orthogonal strategies) .

What criteria should I use when selecting an LLPH antibody for my specific application?

When selecting an LLPH antibody, consider these criteria:

• Application compatibility: Select antibodies validated for your specific application (WB, IF, IP). Interestingly, research shows that success in IF is the best predictor of performance in WB and IP .

• Epitope considerations: For human LLPH, antibodies targeting different regions are available. Some target the central region (amino acids 62-90) , while others target regions from amino acid 50 to C-terminus or amino acids 1-129 .

• Validation method: Prioritize antibodies validated using genetic approaches (KO or knockdown cells) over those validated with orthogonal methods.

• Clonality: Based on performance data, recombinant antibodies generally outperform polyclonal and monoclonal antibodies across applications .

• Species reactivity: Confirm the antibody has been validated in your species of interest (Human, Rat, etc.).

What are the optimal conditions for using LLPH antibodies in Western blotting?

For optimal Western blot results with LLPH antibodies:

• Sample preparation: Use appropriate lysis buffers for intracellular proteins. For secreted forms of LLPH, collect and process cell media.

• Dilution ratios: Most LLPH antibodies work well at dilutions between 1:200-1:2,000 for Western blotting . Some specific antibodies recommend a 1:1000 dilution . Always optimize with a dilution series.

• Molecular weight expectations: Look for bands at approximately 15.2-18 kDa, which is the calculated molecular weight of LLPH protein .

• Controls: Include positive controls (lysates from cells known to express LLPH) and negative controls (lysates from LLPH knockout cells) whenever possible for proper interpretation.

• Blocking conditions: Most protocols use standard blocking with 5% non-fat dry milk or BSA in TBST, but optimize if background issues occur.

How can I optimize immunofluorescence staining using LLPH antibodies?

For successful immunofluorescence with LLPH antibodies:

• Fixation method: Use PFA fixation with Triton X-100 permeabilization, as demonstrated in successful protocols with LLPH antibodies in MCF7 cells .

• Antibody concentration: Start with 4 μg/mL for immunofluorescence staining based on validated protocols .

• Cell types: Consider using cell lines with documented LLPH expression (e.g., MCF7 cells have been successfully used) .

• Controls: Ideally, include a mosaic culture of parental and LLPH-knockout cells in the same visual field to directly compare signals and reduce imaging biases .

• Signal verification: Look for specific subcellular localization patterns. LLPH is associated with the nucleolus .

How do I troubleshoot non-specific binding when using LLPH antibodies?

When encountering non-specific binding:

• Identify the issue: Determine if you're seeing non-specific bands in Western blot or non-specific staining in immunofluorescence.

• Validation status check: Be aware that many antibodies on the market show specific but non-selective binding patterns, detecting their intended target but also recognizing unrelated proteins .

• Dilution optimization: Test a range of antibody dilutions. Too concentrated antibody solutions often increase non-specific binding.

• Blocking optimization: Increase blocking time or try different blocking reagents (BSA vs. milk vs. normal serum).

• Washing stringency: Increase the number or duration of washes, or add mild detergents to washing buffers.

• Consider alternative antibodies: Research shows that recombinant antibodies have higher specificity rates compared to polyclonal or monoclonal antibodies .

Why might my LLPH antibody work for Western blot but not for immunofluorescence?

This discrepancy can occur for several reasons:

• Epitope accessibility: In fixed cells (IF), the LLPH epitope may be masked or altered compared to denatured proteins (WB).

• Fixation sensitivity: Some epitopes are sensitive to particular fixation methods. If a PFA-Triton X-100 protocol isn't working, try alternative fixation methods.

• Application-specific validation: Many antibodies are only validated for specific applications. Research shows that of antibodies recommended for Western blotting, only 44% were successful in standardized testing, while for immunofluorescence, only 39% of recommended antibodies were confirmed successful .

• Concentration requirements: Immunofluorescence typically requires higher antibody concentrations than Western blotting.

• Expression levels: LLPH might be expressed at levels below the detection threshold in your cells of interest for immunofluorescence but detectable after concentration in Western blot samples.

How can I design experiments to study LLPH's role in neuronal development?

To investigate LLPH's role in neuronal development:

• Cell model selection: Use hippocampal neuron cultures, as LLPH is known to regulate dendritic and spine growth and synaptic transmission in these neurons .

• Knockdown/knockout approach: Implement CRISPR/Cas9 knockouts or RNAi knockdowns of LLPH, followed by detailed morphological analysis of:

  • Dendritic arborization

  • Spine density and morphology

  • Synaptic marker distribution

• Rescue experiments: After knockdown/knockout, reintroduce wild-type LLPH or mutant variants to determine functional domains.

• Time-course analysis: Monitor LLPH expression during different stages of neuronal development to identify critical periods.

• Functional assays: Include electrophysiological recordings to assess effects on synaptic transmission, correlating LLPH expression with functional outcomes.

• Colocalization studies: Use validated LLPH antibodies alongside markers for specific neuronal structures to determine precise subcellular localization during development.

What are the considerations for developing custom LLPH antibodies with specific binding properties?

For researchers considering developing custom LLPH antibodies:

How can I integrate LLPH antibody-based techniques with other molecular approaches to understand LLPH function?

To comprehensively study LLPH function:

• Multi-omics approach: Combine antibody-based techniques with:

  • Transcriptomics to identify genes co-regulated with LLPH

  • Proteomics to identify LLPH interaction partners

  • Metabolomics to examine effects on lactate metabolism pathways

• Proximity labeling: Use BioID or APEX2 fusions with LLPH to identify proximal proteins in living cells.

• Live imaging: Combine with fluorescent protein tagging to monitor LLPH dynamics in real-time.

• Structure-function analysis: Use antibodies recognizing specific domains alongside site-directed mutagenesis to correlate structural features with functional outcomes.

• LLPH pathway analysis: Use phospho-specific antibodies (if available) together with kinase inhibitors to place LLPH in signaling pathways.

• Single-cell analysis: Combine antibody-based flow cytometry or imaging with single-cell sequencing to understand cell-to-cell variability in LLPH expression and function.